Certara announced the release of Simcyp Simulator Version 22, which includes new capabilities and updated features to the Company’s population-based modeling and simulation platform. The Simcyp Simulator is the pharmaceutical industry’s most sophisticated physiologically based pharmacokinetics platform and is being applied to small and large molecule drug candidates. The Simcyp Simulator has proven use cases across drug development, including first-in-human dosing, extrapolation to special populations, bioequivalence testing, optimizing clinical study design and predicting drug-drug interactions.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CERT: